Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gynecologic 1

Conditions

Sarcoma 4Osteosarcoma 2Neoplasms 2Chondrosarcoma 2Uterine Neoplasms 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Histiocytoma, Malignant Fibrous 1Dermatofibrosarcoma 1Adenoviridae Infections 1

Interventions

Paclitaxel 2Gemcitabine 2seribantumab 1pembrolizumab 1cemiplimab 1camrelizumab 1apatinib 1Radionuclide Imaging 1Quality of Life 1Patient Reported Outcome Measures 1OSI 930 1Nivolumab 1Molecular Diagnostic Techniques 1Magnetic Resonance Spectroscopy 1Letrozole 1Immunotherapy 1Immune Checkpoint Inhibitors 1Fluorodeoxyglucose F18 1FAPI-46 1FANG vaccine 1Drug Therapy 1Doxorubicin 1Docetaxel 1Cisplatin 1Carboplatin 1Bortezomib 1Biological Therapy 1Axitinib 14-hydroxy-N-desmethyltamoxifen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Neoplasms × Immune Checkpoint Inhibitors × Sarcoma × Clear all
NCT04239443 2020-01-27

Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine Cancer

Hunan Cancer Hospital

Phase 2 Unknown
120 enrolled
GynecologicSarcoma

Sarcoma, Uterine Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡